Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Shun Lu showed data for SYS6010, an EGFR-targeting ADC, at AACR25. Small numbers but very encouraging efficacy in EGFR mutant NSCLC especially post-TKI but pre-chemotherapy with RR 63% (RR 89% at 4.8 mg/kg dose) with expected safety signals (myelosuppression).”
Learn more about EGFR-mutant NSCLC on OncoDaily.
